Meeting
2019 ASCO Annual Meeting
Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma.
Authors
Mohamad Barakat
University of California San Francisco, Fresno, CA
Mohamad Barakat , Maher Albitar , Zijun Xu-Monette , Ken H Young , Haifaa Abdulhaq
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7549)
DOI
10.1200/JCO.2019.37.15_suppl.7549
Abstract #
7549
Poster Bd #
303
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Georg Lenz
Poster
2014 ASCO Annual Meeting
Gene expression analysis of B-cell receptors (BCR) pathway for identification of PDE4B gene as potential therapeutic target to overcome glucocorticoid resistance in primary CNS lymphoma.
First Author: Ariz Akhter
Poster
2022 ASCO Annual Meeting
Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.
First Author: Franck Morschhauser
Poster
2022 ASCO Annual Meeting
Development and validation of Duoseq as a novel diagnostic and companion assay for lymphoma and other cancers.
First Author: Chrissie Rozzi